Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

311P - Evaluation of durvalumab real-world use and effectiveness in first line extensive-stage small-cell lung cancer: Primary results of the ARSENAL study

Date

28 Mar 2025

Session

Poster Display session

Presenters

Jean Bernard Auliac

Citation

Journal of Thoracic Oncology (2025) 20 (3): S181-S207. 10.1016/S1556-0864(25)00632-X

Authors

J.B. Auliac1, C. Decroisette2, C. chouaid3, F. Guisier4, A. Vergnenegre5, V. Leroy6, C. Addi7, N. Goyard8, A. Lahouegue8, F. Marlin8, L. Mounier8, L. Falchero9

Author affiliations

  • 1 CHI - Centre Hospitalier Intercommunal de Créteil, Créteil/FR
  • 2 Centre Léon Bérard, Lyon/FR
  • 3 Service de Pneumologie, CHI Créteil, Créteil/FR
  • 4 CHU de Rouen Normandie, Rouen/FR
  • 5 CHU Limoges - Hopital Dupuytren, Limoges/FR
  • 6 Clinique Teissier, Valenciennes/FR
  • 7 AstraZeneca SAS, 92844 - Courbevoie/FR
  • 8 AstraZeneca SAS, Courbevoie/FR
  • 9 L'Hopital Nord Ouest - Villefranche-Sur-Saone, Villefranche-Sur-Saone/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 311P

Background

Small-cell lung cancer (SCLC) is an aggressive form of lung cancer associated with poor prognosis. In 2020, durvalumab (D) combined with platinum-etoposide (PE) was approved for extensive-stage (ES) SCLC based on efficacy demonstrated in the CASPIAN trial. The ARSENAL study aims to complement those results with real-world (rw) evidence on the effectiveness and use of D in ES-SCLC.

Methods

This prospective, observational study was conducted in 33 sites in France in patients (pts) newly treated with D plus PE for ES-SCLC between Nov 2022 and Feb 2024. Pts were regularly followed up at D0 (first infusion of D and/or PE),weeks 6 and 12 and subsequently every 2 to 3 months. Primary and secondary outcomes were Time To Discontinuation (TTD) and rw Progression Free Survival (PFS).

Results

232 pts initiated D, of whom 213 were included in the interim analysis with a median follow up of 10.4 months (mo) (IQR 6.6–13.9). At baseline, pts had a median age of 69 years (IQR 62–74), with 67.1% aged ≥65 years. 63.8% were male and 97.8% were current or former smokers. The ECOG PS distribution was 16.6%, 61.3%, 18.6%, and 3.5% for PS 0, 1, 2, and 3, respectively. The main metastatic sites were liver (48%), bone (41%), and brain (21%). D was combined with E and carboplatin in 98.1% of pts, with only 1.9% (n=4) receiving cisplatin. The treatment included a median of 4 induction cycles (D+PE), and a median of 2 maintenance cycles (D alone). Overall, 121 pts (58.2%) discontinued D, primarily due to progression (59.5%), death (14.9%), or adverse events (AEs) (9.1%). The median TTD was estimated at 5.6 months (95% CI 4.9–6.0), with a 6-mo TTD rate of 40.6% (95% CI 32.6–48.5). Median PFS was 5.1 months (95% CI 4.6–6.2), with a 6-mo PFS rate of 45.4% (95% CI 37.5–53.3). Treatment-related grade ≥3 AEs were reported in 27 (11.6%) pts with anemia and thrombocytopenia being the most frequent.

Conclusions

The effectiveness results of this first interim analysis from ARSENAL rw study are consistent with CASPIAN study (median PFS was 5.1 months in the D arm), although the study population was older and frailer. ARSENAL is, to our knowledge, the rw study in ES-SCLC pts treated with durvalumab and platinum-based chemotherapy with the highest prevalence of PS2+ pts.

Clinical trial identification

NCT05683977.

Editorial acknowledgement

The authors also thank Kappa Santé for the project management, monitoring, data management, statistics and medical writing assistance.

Legal entity responsible for the study

AstraZeneca France.

Funding

AstraZeneca France.

Disclosure

C. Decroisette: Financial Interests, Personal, Advisory Board: BMS, MSD, Roche, Takeda, Pfizer, Sanofi, AstraZeneca, Amgen, Janssen, Novartis, Danone, Novocure, Regeneron; Financial Interests, Personal, Invited Speaker: MSD, Amgen, Pfizer, Regeneron, Takeda. J.B. Auliac: Financial Interests, Personal, Advisory Board: Boehringer Ingelheim, Hoffman-Roche, Takeda, BMS, MSD, Sanofi, AstraZeneca, Amgen, Janssen, Pfizer. C. Chouaid: Financial Interests, Personal, Research Grant: AbbVie, Amgen, AstraZeneca, BeiGene, Boehringer Ingelheim, BMS, Daiichi Sankyo, Gilead, F. Hoffmann-La Roche, Janssen, LeoPharma, Lilly, Merk Serono, MSD, Novartis, Sanofi; Financial Interests, Personal, Advisory Board: AbbVie, Amgen, AstraZeneca, BeiGene, BMS, Daiichi Sankyo, Gilead, Ipsen, F. Hoffmann-La Roche, Janssen, LeoPharma, Lilly, MSD, Novocure, Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi, Takeda. F. Guisier: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, BMS, Janssen, MSD, Pfizer, Roche, Sanofi, Takeda, Viatris; Financial Interests, Personal, Research Grant: Janssen, Roche, Takeda. A. Vergnenegre: Financial Interests, Personal, Advisory Role: Pierre Fabre, Amgen, MSD; Financial Interests, Personal, Advisory Board: MSD, AstraZeneca, Sanofi, Amgen, Pierre Fabre. V. Leroy: Financial Interests, Personal, Advisory Board: AstraZeneca, Amgen, Roche. C. Addi, N. Goyard, A. Lahouegue, F. Marlin, L. Mounier: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. L. Falchero: Financial Interests, Personal, Advisory Board: MSD, BMS, AstraZeneca, Roche, Amgen, Takeda.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.